SAN DIEGO, April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Compensation Committee of its Board of Directors granted an inducement award to Kristin Yarema, the Company's new President, Cell Therapy. This grant is made pursuant to the Company's 2022 Inducement Plan as an inducement material to Ms. Yarema entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more at prnewswire.comPoseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
